MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 2 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

afffundunlabeled
Novel Approaches for Targeted Cancer Therapy
Veronique Guillemard, H. Uri Saragovi
2004· review· en· Current Cancer Drug Targets· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · metaepi_narrow
80
citations
affno abstractunlabeled
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma
Sarah M. Bronner, Karl A. Merrick, Jeremy Murray, Laurent Salphati, John G. Moffat, Jodie Pang +29 more
2019· article· en· Bioorganic & Medicinal Chemistry Letters· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
64
citations
affunlabeled
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with <i>PIK3CA-</i>mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.
Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz Borrego, Patrick Neven +10 more
2020· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
56
citations
affno abstractunlabeled
Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Dennis J. Slamon, Patrick Neven, Stephen Chia, PA Fasching, Michelino De Laurentiis, S.-A. Im +14 more
2019· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
54
citations
affunlabeled
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Susana Banerjee, Sandro Pignata, Nicoletta Colombo +14 more
2023· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
53
citations
affunlabeled
CCI-779 Wyeth.
Laurie Elit
2002· article· en· PubMed· Medicine
distilled prediction:candidate · noneconsensus · none
43
citations
affno abstractunlabeled
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials
Allan Ramos-Esquivel, Hellen Hernández-Steller, Marie-France Savard, Denis Landaverde
2018· review· en· Breast Cancer· Medicine
distilled prediction:candidate · metaepi_narrow+metaepi_broad+insufficient_payloadconsensus · metaepi_narrow+metaepi_broad
43
citations
← previousnext →

How this was built: Screen · Findings · About